Japanese REal-world data for treatment of afatinib (GIotrif®) in first-line setting and Subsequent Therapies for patients with advanced EGFR mutation-positive lung adenocarcinoma (J-REGISTER) First published 26/03/2021 Last updated 17/12/2025 EU PAS number:EUPAS40322 Study Finalised